This finding was indicative of the directly contrasting results for rates of major adverse cardiac events at 1-year follow up ( zotarolimus 93/1162 [ 8.0 % ] vs sirolimus 46/1170 [ 3.9 % ] ; OR 2.13 , 95 % CI 1.48-3 .07 ; p < 0.0001 ) compared with those at follow-up between 1 and 5 years ( 104 [ 9.0 % ] vs 136 [ 11.6 % ] ; OR 0.78 , 95 % CI 0.59-1 .02 ; p = 0.071 ) .